Retaklik vs Retatrutide: Are They the Same Thing? (UK Guide 2026)

If you have been comparing research peptides, you have probably hit this exact moment of confusion: one site says retatrutide, another says Retaklik, and you are left wondering whether you are looking at two different things or the same thing wearing a different hat. It is a fair question, and the internet does a stellar job of muddying it. So let us settle it plainly: is Retaklik the same as retatrutide?

Key takeaways

• Retatrutide is the name of the compound — Eli Lilly’s investigational triple-agonist, LY3437943.
• Retaklik is a brand of retatrutide research pens — not a separate molecule.
• Important nuance: Retaklik 2.0 is not pure retatrutide — it is a combination of retatrutide + cagrilintide (an amylin analogue), so it is not the same thing as a plain retatrutide vial.
• Research-supplied peptides are not the formulation used in clinical trials — which is exactly why a COA matters.

The short answer

Retaklik is a brand name for retatrutide research pens — so in its basic form, “Retaklik” and “retatrutide” point to the same compound, just with the brand on the box. But there is a catch worth knowing: the popular Retaklik 2.0 is a combination product — retatrutide plus cagrilintide — so that particular version is not identical to a plain retatrutide vial. Think of it like coffee: “retatrutide” is the espresso; basic Retaklik is that espresso with a brand name; Retaklik 2.0 is the espresso with an extra shot of something else stirred in. Same base, different drink.

What is retatrutide?

Retatrutide is a single peptide that activates three receptors at once — GLP-1, GIP and glucagon — which is why researchers describe it as a “triple agonist”. It is being developed by Eli Lilly and is still in clinical trials; its Phase 2 data was published in the New England Journal of Medicine, and Lilly has summarised the programme in its own investor release. For the full molecular detail, see our retatrutide research compound profile.

So what is Retaklik?

Retaklik is a brand name used for retatrutide presented in a pre-set research pen, as opposed to a traditional vial-and-syringe setup. The appeal of the pen format is convenience for measured research handling — the “klik” in the name is a nod to the click-dose mechanism. In its standard form the compound it delivers is retatrutide. We cover the pen specifically in our Retaklik UK guide, including how the dial works.

And what is Retaklik 2.0? (the bit people miss)

This is where the “are they the same?” question gets a genuine twist. Retaklik 2.0 is a combination research pen: retatrutide + cagrilintide. Cagrilintide is a long-acting amylin analogue — a different class of peptide being studied alongside incretin compounds in metabolic research. So Retaklik 2.0 contains retatrutide, but it is not only retatrutide. If you specifically want plain retatrutide, a 2.0 combination pen is not a like-for-like swap — check the box, which states the compounds and amounts (for example, a 40 + 5 split). The label is the source of truth.

Vial vs pen vs combination: a quick comparison

	Retatrutide vial	Retaklik (standard pen)	Retaklik 2.0 pen
Compound(s)	Retatrutide	Retatrutide	Retatrutide + cagrilintide
Format	Freeze-dried powder, reconstituted by you	Pre-set research pen	Pre-set research pen
Setup	Requires reconstitution (see our guide)	Convenient, less prep	Convenient, less prep
Same as plain retatrutide?	Yes	Yes (brand format)	No — it’s a combination

So “which is better” depends entirely on what your research calls for. Want flexibility and control over concentration? The vial. Want convenience with plain retatrutide? The standard pen. Specifically researching the retatrutide-plus-amylin combination? That is what 2.0 is for — just go in knowing it is a different product, not a rebranded one.

The important caveat nobody should skip

Here is the bit the hype merchants gloss over. Research-supplied retatrutide — whether labelled Retaklik, Retaklik 2.0, or sold as a plain vial — is not the identical, regulator-checked formulation used in Eli Lilly’s clinical trials. It is supplied for laboratory research only, and quality genuinely varies between suppliers. Retatrutide has no MHRA authorisation and cannot legally be sold as a medicine in the UK. That is not a technicality; it is the whole reason a batch-specific Certificate of Analysis matters. The brand on the box tells you the format. The COA tells you the truth.

What to check before you buy any of them

• Read the label — is it plain retatrutide, or a 2.0 combination with cagrilintide? Know which you are buying.
• A batch-specific third-party COA (Janoshik or similar) confirming identity and ≥99% purity.
• Honest research-use-only labelling — no miracle claims.
• A real UK supplier with dispatch and support.
• Sensible pricing — see our retatrutide UK price guide.

You can see current UK stock on our retatrutide UK page, including retatrutide 2.0 (45mg).

Frequently asked questions

Is Retaklik the same as retatrutide?

In its standard form, yes — Retaklik is a branded research-pen format that delivers retatrutide. But Retaklik 2.0 is a combination of retatrutide and cagrilintide, so that version is not the same as plain retatrutide. Always check the label.

What is in Retaklik 2.0?

Retaklik 2.0 is a combination research pen containing retatrutide plus cagrilintide (an amylin analogue). The box states the compounds and amounts.

What is cagrilintide?

Cagrilintide is a long-acting amylin analogue — a different class of research peptide studied alongside incretin compounds such as retatrutide.

Is Retaklik 2.0 the same as the retatrutide used in trials?

No. Research-supplied peptides — under any brand, and especially combinations — are not the regulator-verified clinical-trial formulation. Rely on a batch COA for what is actually in the product.

Which should I choose, vial, pen or 2.0?

The vial offers control over concentration; the standard pen offers convenience with plain retatrutide; Retaklik 2.0 is for research into the retatrutide-plus-cagrilintide combination specifically. Pick based on what you are actually researching.

Is Retaklik legal in the UK?

Retatrutide is not a controlled drug, but it has no UK medicine authorisation, so Retaklik, Retaklik 2.0 and retatrutide can only be sold for research use — not for human consumption.

The bottom line

Retaklik and retatrutide are not two rival compounds — Retaklik is a branded retatrutide research pen. The twist is Retaklik 2.0, which adds cagrilintide, so it is a combination rather than plain retatrutide. Read the label to know which you are getting, then choose your supplier on the COA. Browse current stock on our retatrutide UK page.

This article is for informational and research purposes only. Retatrutide and cagrilintide are investigational compounds supplied for laboratory research use only and are not for human consumption. Nothing here is medical advice.